Part 2: When Should Bisphosphonates Be Used in Children with Chronic Illness Osteoporosis?
Purpose of Review Part 1 of this review on secondary osteoporosis of childhood was devoted to understanding which children should undergo bone health monitoring, when to label a child with osteoporosis in this setting, and how best to monitor in order to identify early, rather than late, signs of bo...
Gespeichert in:
Veröffentlicht in: | Current osteoporosis reports 2021-06, Vol.19 (3), p.289-297 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 297 |
---|---|
container_issue | 3 |
container_start_page | 289 |
container_title | Current osteoporosis reports |
container_volume | 19 |
creator | Ward, Leanne M. |
description | Purpose of Review
Part 1 of this review on secondary osteoporosis of childhood was devoted to understanding which children should undergo bone health monitoring, when to label a child with osteoporosis in this setting, and how best to monitor in order to identify early, rather than late, signs of bone fragility. In Part 2 of this review, we discuss the next critical step in deciding which children require bisphosphonate therapy. This involves distinguishing which children have the potential to undergo “medication-unassisted” recovery from secondary osteoporosis, obviating the need for bisphosphonate administration, from those who require anti-resorptive therapy in order to recover from osteoporosis.
Recent Findings
Unlike children with primary osteoporosis such as osteogenesis imperfecta, where the potential for recovery from osteoporosis without medical therapy is limited, many children with secondary osteoporosis can undergo complete recovery in the absence of bisphosphonate intervention. Over the last decade, natural history studies have unveiled the spectrum of this recovery, which spans overt deterioration (i.e., incident vertebral and non-vertebral fractures and declines in bone mineral density (BMD)), to spectacular reclamation of BMD, and complete restoration of normal vertebral dimensions after spine fractures. The fact that reshaping of vertebral bodies following fractures is growth-dependent underscores the need to identify and treat those at risk for permanent vertebral deformity in a timely fashion.
Summary
The decision to treat a child with a bisphosphonate hinges on distinguishing bone fragility from typical childhood fractures, and determining the potential for medication-unassisted recovery following an osteoporotic fragility fracture. While improvements in BMD are a well-known sign of recovery, restitution of bone structure is also a key indicator of recuperation, one that is unique to childhood, and that plays a pivotal role in the decision to intervene or not. |
doi_str_mv | 10.1007/s11914-021-00672-0 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2543455411</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2543455411</sourcerecordid><originalsourceid>FETCH-LOGICAL-c347t-7987238541c07ea9ab2fecb426931518458c99d9a1652e5ca13be15d9a7ccbb13</originalsourceid><addsrcrecordid>eNp9kE1P3DAQhi1EBZT2D3BAPnIJ9fhjnXBBsIIWCQmkgir1YjnOLAnKxosnEeq_x8suHHuwxh4_88p-GDsCcQpC2B8EUIEuhIRCiJmVhdhhB2C0LqTUsLvdQ2nVPvtK9CyElKDVHttXGvRManvA_t77NHJ5xv-0OPDfbZz6hl92tGrjeg1-ROKXyB8JG94NfN52fZMy-tqNbT6lOHSB3_T9gET8jkaMq5gidXT-jX1Z-J7w-7Yessfrq4f5r-L27ufN_OK2CErbsbBVaaUqjYYgLPrK13KBodZyVikwUGpThqpqKg8zI9EED6pGMLlhQ6hrUIfsZJO7SvFlQhrdsqOAfe8HjBM5abTSJuevUblBQ34iJVy4VeqWPv1zINzaqds4ddmpe3fqRB463uZP9RKbz5EPiRlQG4Dy1fCEyT3HKQ35z_-LfQMeyoDO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2543455411</pqid></control><display><type>article</type><title>Part 2: When Should Bisphosphonates Be Used in Children with Chronic Illness Osteoporosis?</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Ward, Leanne M.</creator><creatorcontrib>Ward, Leanne M.</creatorcontrib><description>Purpose of Review
Part 1 of this review on secondary osteoporosis of childhood was devoted to understanding which children should undergo bone health monitoring, when to label a child with osteoporosis in this setting, and how best to monitor in order to identify early, rather than late, signs of bone fragility. In Part 2 of this review, we discuss the next critical step in deciding which children require bisphosphonate therapy. This involves distinguishing which children have the potential to undergo “medication-unassisted” recovery from secondary osteoporosis, obviating the need for bisphosphonate administration, from those who require anti-resorptive therapy in order to recover from osteoporosis.
Recent Findings
Unlike children with primary osteoporosis such as osteogenesis imperfecta, where the potential for recovery from osteoporosis without medical therapy is limited, many children with secondary osteoporosis can undergo complete recovery in the absence of bisphosphonate intervention. Over the last decade, natural history studies have unveiled the spectrum of this recovery, which spans overt deterioration (i.e., incident vertebral and non-vertebral fractures and declines in bone mineral density (BMD)), to spectacular reclamation of BMD, and complete restoration of normal vertebral dimensions after spine fractures. The fact that reshaping of vertebral bodies following fractures is growth-dependent underscores the need to identify and treat those at risk for permanent vertebral deformity in a timely fashion.
Summary
The decision to treat a child with a bisphosphonate hinges on distinguishing bone fragility from typical childhood fractures, and determining the potential for medication-unassisted recovery following an osteoporotic fragility fracture. While improvements in BMD are a well-known sign of recovery, restitution of bone structure is also a key indicator of recuperation, one that is unique to childhood, and that plays a pivotal role in the decision to intervene or not.</description><identifier>ISSN: 1544-1873</identifier><identifier>EISSN: 1544-2241</identifier><identifier>DOI: 10.1007/s11914-021-00672-0</identifier><identifier>PMID: 34146247</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Bone Density ; Bone Density Conservation Agents - therapeutic use ; Child ; Chronic Disease ; Diphosphonates - therapeutic use ; Epidemiology ; Humans ; Medicine ; Medicine & Public Health ; Orthopedics ; Osteoporosis - prevention & control ; Osteoporotic Fractures - prevention & control ; Pediatrics (C Munns and F Rauch ; Secondary Prevention ; Section Editors ; Topical Collection on Pediatrics</subject><ispartof>Current osteoporosis reports, 2021-06, Vol.19 (3), p.289-297</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c347t-7987238541c07ea9ab2fecb426931518458c99d9a1652e5ca13be15d9a7ccbb13</citedby><cites>FETCH-LOGICAL-c347t-7987238541c07ea9ab2fecb426931518458c99d9a1652e5ca13be15d9a7ccbb13</cites><orcidid>0000-0003-1557-9185</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11914-021-00672-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11914-021-00672-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34146247$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ward, Leanne M.</creatorcontrib><title>Part 2: When Should Bisphosphonates Be Used in Children with Chronic Illness Osteoporosis?</title><title>Current osteoporosis reports</title><addtitle>Curr Osteoporos Rep</addtitle><addtitle>Curr Osteoporos Rep</addtitle><description>Purpose of Review
Part 1 of this review on secondary osteoporosis of childhood was devoted to understanding which children should undergo bone health monitoring, when to label a child with osteoporosis in this setting, and how best to monitor in order to identify early, rather than late, signs of bone fragility. In Part 2 of this review, we discuss the next critical step in deciding which children require bisphosphonate therapy. This involves distinguishing which children have the potential to undergo “medication-unassisted” recovery from secondary osteoporosis, obviating the need for bisphosphonate administration, from those who require anti-resorptive therapy in order to recover from osteoporosis.
Recent Findings
Unlike children with primary osteoporosis such as osteogenesis imperfecta, where the potential for recovery from osteoporosis without medical therapy is limited, many children with secondary osteoporosis can undergo complete recovery in the absence of bisphosphonate intervention. Over the last decade, natural history studies have unveiled the spectrum of this recovery, which spans overt deterioration (i.e., incident vertebral and non-vertebral fractures and declines in bone mineral density (BMD)), to spectacular reclamation of BMD, and complete restoration of normal vertebral dimensions after spine fractures. The fact that reshaping of vertebral bodies following fractures is growth-dependent underscores the need to identify and treat those at risk for permanent vertebral deformity in a timely fashion.
Summary
The decision to treat a child with a bisphosphonate hinges on distinguishing bone fragility from typical childhood fractures, and determining the potential for medication-unassisted recovery following an osteoporotic fragility fracture. While improvements in BMD are a well-known sign of recovery, restitution of bone structure is also a key indicator of recuperation, one that is unique to childhood, and that plays a pivotal role in the decision to intervene or not.</description><subject>Bone Density</subject><subject>Bone Density Conservation Agents - therapeutic use</subject><subject>Child</subject><subject>Chronic Disease</subject><subject>Diphosphonates - therapeutic use</subject><subject>Epidemiology</subject><subject>Humans</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Orthopedics</subject><subject>Osteoporosis - prevention & control</subject><subject>Osteoporotic Fractures - prevention & control</subject><subject>Pediatrics (C Munns and F Rauch</subject><subject>Secondary Prevention</subject><subject>Section Editors</subject><subject>Topical Collection on Pediatrics</subject><issn>1544-1873</issn><issn>1544-2241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1P3DAQhi1EBZT2D3BAPnIJ9fhjnXBBsIIWCQmkgir1YjnOLAnKxosnEeq_x8suHHuwxh4_88p-GDsCcQpC2B8EUIEuhIRCiJmVhdhhB2C0LqTUsLvdQ2nVPvtK9CyElKDVHttXGvRManvA_t77NHJ5xv-0OPDfbZz6hl92tGrjeg1-ROKXyB8JG94NfN52fZMy-tqNbT6lOHSB3_T9gET8jkaMq5gidXT-jX1Z-J7w-7Yessfrq4f5r-L27ufN_OK2CErbsbBVaaUqjYYgLPrK13KBodZyVikwUGpThqpqKg8zI9EED6pGMLlhQ6hrUIfsZJO7SvFlQhrdsqOAfe8HjBM5abTSJuevUblBQ34iJVy4VeqWPv1zINzaqds4ddmpe3fqRB463uZP9RKbz5EPiRlQG4Dy1fCEyT3HKQ35z_-LfQMeyoDO</recordid><startdate>20210601</startdate><enddate>20210601</enddate><creator>Ward, Leanne M.</creator><general>Springer US</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1557-9185</orcidid></search><sort><creationdate>20210601</creationdate><title>Part 2: When Should Bisphosphonates Be Used in Children with Chronic Illness Osteoporosis?</title><author>Ward, Leanne M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c347t-7987238541c07ea9ab2fecb426931518458c99d9a1652e5ca13be15d9a7ccbb13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Bone Density</topic><topic>Bone Density Conservation Agents - therapeutic use</topic><topic>Child</topic><topic>Chronic Disease</topic><topic>Diphosphonates - therapeutic use</topic><topic>Epidemiology</topic><topic>Humans</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Orthopedics</topic><topic>Osteoporosis - prevention & control</topic><topic>Osteoporotic Fractures - prevention & control</topic><topic>Pediatrics (C Munns and F Rauch</topic><topic>Secondary Prevention</topic><topic>Section Editors</topic><topic>Topical Collection on Pediatrics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ward, Leanne M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current osteoporosis reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ward, Leanne M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Part 2: When Should Bisphosphonates Be Used in Children with Chronic Illness Osteoporosis?</atitle><jtitle>Current osteoporosis reports</jtitle><stitle>Curr Osteoporos Rep</stitle><addtitle>Curr Osteoporos Rep</addtitle><date>2021-06-01</date><risdate>2021</risdate><volume>19</volume><issue>3</issue><spage>289</spage><epage>297</epage><pages>289-297</pages><issn>1544-1873</issn><eissn>1544-2241</eissn><abstract>Purpose of Review
Part 1 of this review on secondary osteoporosis of childhood was devoted to understanding which children should undergo bone health monitoring, when to label a child with osteoporosis in this setting, and how best to monitor in order to identify early, rather than late, signs of bone fragility. In Part 2 of this review, we discuss the next critical step in deciding which children require bisphosphonate therapy. This involves distinguishing which children have the potential to undergo “medication-unassisted” recovery from secondary osteoporosis, obviating the need for bisphosphonate administration, from those who require anti-resorptive therapy in order to recover from osteoporosis.
Recent Findings
Unlike children with primary osteoporosis such as osteogenesis imperfecta, where the potential for recovery from osteoporosis without medical therapy is limited, many children with secondary osteoporosis can undergo complete recovery in the absence of bisphosphonate intervention. Over the last decade, natural history studies have unveiled the spectrum of this recovery, which spans overt deterioration (i.e., incident vertebral and non-vertebral fractures and declines in bone mineral density (BMD)), to spectacular reclamation of BMD, and complete restoration of normal vertebral dimensions after spine fractures. The fact that reshaping of vertebral bodies following fractures is growth-dependent underscores the need to identify and treat those at risk for permanent vertebral deformity in a timely fashion.
Summary
The decision to treat a child with a bisphosphonate hinges on distinguishing bone fragility from typical childhood fractures, and determining the potential for medication-unassisted recovery following an osteoporotic fragility fracture. While improvements in BMD are a well-known sign of recovery, restitution of bone structure is also a key indicator of recuperation, one that is unique to childhood, and that plays a pivotal role in the decision to intervene or not.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>34146247</pmid><doi>10.1007/s11914-021-00672-0</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-1557-9185</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1544-1873 |
ispartof | Current osteoporosis reports, 2021-06, Vol.19 (3), p.289-297 |
issn | 1544-1873 1544-2241 |
language | eng |
recordid | cdi_proquest_miscellaneous_2543455411 |
source | MEDLINE; Springer Nature - Complete Springer Journals |
subjects | Bone Density Bone Density Conservation Agents - therapeutic use Child Chronic Disease Diphosphonates - therapeutic use Epidemiology Humans Medicine Medicine & Public Health Orthopedics Osteoporosis - prevention & control Osteoporotic Fractures - prevention & control Pediatrics (C Munns and F Rauch Secondary Prevention Section Editors Topical Collection on Pediatrics |
title | Part 2: When Should Bisphosphonates Be Used in Children with Chronic Illness Osteoporosis? |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T00%3A40%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Part%202:%20When%20Should%20Bisphosphonates%20Be%20Used%20in%20Children%20with%20Chronic%20Illness%20Osteoporosis?&rft.jtitle=Current%20osteoporosis%20reports&rft.au=Ward,%20Leanne%20M.&rft.date=2021-06-01&rft.volume=19&rft.issue=3&rft.spage=289&rft.epage=297&rft.pages=289-297&rft.issn=1544-1873&rft.eissn=1544-2241&rft_id=info:doi/10.1007/s11914-021-00672-0&rft_dat=%3Cproquest_cross%3E2543455411%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2543455411&rft_id=info:pmid/34146247&rfr_iscdi=true |